These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35144331)

  • 21. dRiskKB: a large-scale disease-disease risk relationship knowledge base constructed from biomedical text.
    Xu R; Li L; Wang Q
    BMC Bioinformatics; 2014 Apr; 15():105. PubMed ID: 24725842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational drug repositioning through heterogeneous network clustering.
    Wu C; Gudivada RC; Aronow BJ; Jegga AG
    BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S6. PubMed ID: 24564976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Network mirroring for drug repositioning.
    Park S; Lee DG; Shin H
    BMC Med Inform Decis Mak; 2017 May; 17(Suppl 1):55. PubMed ID: 28539121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational drug repositioning using meta-path-based semantic network analysis.
    Tian Z; Teng Z; Cheng S; Guo M
    BMC Syst Biol; 2018 Dec; 12(Suppl 9):134. PubMed ID: 30598084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study.
    Wysham CH; Gauthier-Loiselle M; Bailey RA; Manceur AM; Lefebvre P; Greenberg M; Duh MS; Young JB
    Curr Med Res Opin; 2020 Feb; 36(2):219-227. PubMed ID: 31625766
    [No Abstract]   [Full Text] [Related]  

  • 26. Type 2 diabetes in midlife and risk of cerebrovascular disease in late life: a prospective nested case-control study in a nationwide Swedish twin cohort.
    Yang R; Pedersen NL; Bao C; Xu W; Xu H; Song R; Qi X; Xu W
    Diabetologia; 2019 Aug; 62(8):1403-1411. PubMed ID: 31172222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
    Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
    Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns.
    Salentin S; Adasme MF; Heinrich JC; Haupt VJ; Daminelli S; Zhang Y; Schroeder M
    Sci Rep; 2017 Sep; 7(1):11401. PubMed ID: 28900272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug repositioning: a brief overview.
    Jourdan JP; Bureau R; Rochais C; Dallemagne P
    J Pharm Pharmacol; 2020 Sep; 72(9):1145-1151. PubMed ID: 32301512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.
    Adasme MF; Parisi D; Van Belle K; Salentin S; Haupt VJ; Jennings GS; Heinrich JC; Herman J; Sprangers B; Louat T; Moreau Y; Schroeder M
    PLoS One; 2020; 15(5):e0233089. PubMed ID: 32459810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in comorbidity burden and treatment patterns in type 2 diabetes: Longitudinal data from a US cohort from 2006 to 2014.
    Weng W; Liang Y; Kimball E; Hobbs T; Kong S
    Diabetes Res Clin Pract; 2018 Aug; 142():345-352. PubMed ID: 29802955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing Drugs to Target the Diabetes Epidemic.
    Turner N; Zeng XY; Osborne B; Rogers S; Ye JM
    Trends Pharmacol Sci; 2016 May; 37(5):379-389. PubMed ID: 26900045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leveraging Population-Based Clinical Quantitative Phenotyping for Drug Repositioning.
    Brown AS; Rasooly D; Patel CJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Feb; 7(2):124-129. PubMed ID: 28941007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Drug Repositioning Approach Based on Collaborative Metric Learning.
    Luo H; Wang J; Yan C; Li M; Wu FX; Pan Y
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(2):463-471. PubMed ID: 31283509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study.
    Lee MS; Lin RY; Lai MS
    J Am Acad Dermatol; 2014 Apr; 70(4):691-698. PubMed ID: 24411084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis.
    Grammer AC; Ryals MM; Heuer SE; Robl RD; Madamanchi S; Davis LS; Lauwerys B; Catalina MD; Lipsky PE
    Lupus; 2016 Sep; 25(10):1150-70. PubMed ID: 27497259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational Drug Repositioning with Random Walk on a Heterogeneous Network.
    Luo H; Wang J; Li M; Luo J; Ni P; Zhao K; Wu FX; Pan Y
    IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(6):1890-1900. PubMed ID: 29994051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning.
    Wang R; Li S; Cheng L; Wong MH; Leung KS
    BMC Bioinformatics; 2019 Dec; 20(Suppl 26):628. PubMed ID: 31839008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug repositioning through integration of prior knowledge and projections of drugs and diseases.
    Xuan P; Cao Y; Zhang T; Wang X; Pan S; Shen T
    Bioinformatics; 2019 Oct; 35(20):4108-4119. PubMed ID: 30865257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.